Medscape: AFIRE encourages less antiplatelet use with novel oral anticoagulant for atrial fibrillation treatment
UC cardiologist weighs in on trial looking at therapies for heart patients
Medscape turned to the expertise of Richard Becker, MD, Director, UC Heart, Lung and Vascular Institute, when reporting the results of a randomized trial comparing an oral anticoagulation with an antiplatelet agent versus an oral anticoagulation alone in patients with both atrial fibrillation and stable coronary artery disease. Becker, also director of the UC Division of Cardiovascular Health and Disease in the College of Medicine and a UC Health cardiologist, authored a New England Journal of Medicine editorial on the results of the AFIRE trial.
Richard Becker, MD
Related Stories
6 ways starting a GLP-1 medication could affect your emotions
May 20, 2026
When patients first start taking a glucagon-like peptide-1 (GLP-1) medication, they probably expect to feel full. But they might not anticipate how it can influence their emotions. The medications act on the stomach and the brain, said Malti Vij, MD, a University of Cincinnati adjunct associate professor in the College of Medicine's Department of Internal Medicine and a diplomate of the American Board of Obesity Medicine.
UC researchers recruit older adults for extreme heat health study
May 20, 2026
The University of Cincinnati’s Center for Collaboration on Climate & Community for Health (C4H) is recruiting older adults to participate in a study tracking their health during periods of extreme summer heat.
$15 million bequest supports endowed chair at UC College of Medicine
May 19, 2026
As a student and resident at the University of Cincinnati College of Medicine, George G. Bemis, Jr., MD, Med ’64, saw firsthand that medicine was more than a profession for those teaching and leading him. Inspired by their sense of calling, he knew he wanted to pursue the same path.